ProCE Banner Activity

CE / CME

Identification and Management of Immune-Related Adverse Events

Video

On-demand webcast of expert faculty presentation and case discussion on identifying and managing immune-related adverse events in NSCLC being treated with immunotherapy from the advanced practice provider perspective.

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: July 30, 2024

Expiration: July 29, 2025

Share

Faculty

Marianne Davies

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager, Care Signature
Oncology Service Line
Yale New Haven Health
Oncology Nurse Practitioner- Senior APP II
Smilow Cancer Hospital, Yale-New Haven
Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

Kelly E.H. Goodwin

Kelly E.H. Goodwin, NP

Nurse Practitioner, Center for Thoracic Oncology 
Ambulatory Oncology APP Co-Director
Director, Oncology APP Professional Development
Infusion Service Line APP Director
Massachusetts General Hospital
Boston, Massachusetts

Sam Vafadar

Sam Vafadar, DHSc, PA-C

Physician Associate
Thoracic Medical Oncology
Moffitt Cancer Center & Research Institute
Tampa, Florida

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Target Audience

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with NSCLC.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Describe the rationale for neoadjuvant immunotherapy in early-stage NSCLC and considerations that can influence subsequent management of patients

  • Formulate personalized therapeutic strategies for neoadjuvant and adjuvant immunotherapy in patients with NSCLC, based on expert recommendations, current indications, and available efficacy and safety evidence

  • Apply clinical trial evidence, expert guidance, patient preferences, and predictive biomarkers to create ICI-based treatment plans for patients with advanced or metastatic NSCLC

  • Implement evidence-based strategies to monitor and manage irAEs associated with immunotherapy, including patient education on toxicities and strategies to address barriers to optimal care

Disclosure

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager, Care Signature
Oncology Service Line
Yale New Haven Health
Oncology Nurse Practitioner- Senior APP II
Smilow Cancer Hospital, Yale-New Haven
Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

Marianne Davies, DNP, ACNP, AOCNP, FAAN, has no relevant financial relationships to disclose.

Kelly E.H. Goodwin, NP

Nurse Practitioner, Center for Thoracic Oncology 
Ambulatory Oncology APP Co-Director
Director, Oncology APP Professional Development
Infusion Service Line APP Director
Massachusetts General Hospital
Boston, Massachusetts

Kelly E.H. Goodwin, NP, has no relevant financial relationships to disclose.

Sam Vafadar, DHSc, PA-C

Physician Associate
Thoracic Medical Oncology
Moffitt Cancer Center & Research Institute
Tampa, Florida

Sam Vafadar, DHSc, PA-C: consultant/advisor/speaker: Cardinal Health, G1 Therapeutics, Guardant Health.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 30, 2024, through July 29, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours, including 0.5 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until July 29, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation


This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.